NuCana Soars as FDA Fast Tracks Potential Drug for Biliary Tract Cancer By Investing.com
By Dhirendra Tripathi
Investing.com – NuCana stock (NASDAQ:) climbed 22% in Wednesday’s premarket trading as the Food and Drug Administration fast-tracked the company’s experimental drug for treatment of biliary tract cancer.
In a Phase-III trial, the drug called “Cernrin” is being tested for first-line treatment.
FDA announced that regulators will be in constant contact throughout the drug development process. If the drug conforms to FDA standards, this will allow for quick resolution of any issues and enable patients and physicians to access drugs sooner.
If there is no other treatment or the solution proposed has been proven superior to the existing therapy, a drug can be fast tracked.
The biliary tube includes the gallbladder as well as interconnecting conduits which transport bile between the liver, gallbladder, and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the U.S.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.